Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | MMP2 | P08253 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | MMP1 | P03956 | 1/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.65 |
| ▸ | MMP8 | P22894 | 1/20 | 0.65 |
| ▸ | MMP13 | P45452 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | F2 | P00734 | 2/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875177 | 0.84 | CA2 (0.60) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL922350 | 0.82 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL13590904 | 0.82 | CA2 (0.75) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL19999277 | 0.82 | CA2 (0.65) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL6840610 | 0.81 | CA2 (0.64) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL1701616 | 0.79 | CA2 (0.67) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL4495753 | 0.79 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL1700168 | 0.79 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL2956545 | 0.79 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL12000920 | 0.79 | CA2 (1.00) | CA2MMP2CA1MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| EP-1807081-A1 | CYCLOHEXYLDIAMINES AS SELECTIVE ALPHA 1A/1D ADRENORECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY AND LOWER URINARY TRACT SYMPTOMS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060173015-A1 | Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-03 | — | — | US | disclosed |
| WO-2006050048-A1 | CYCLOHEXYLDIAMINES AS SELECTIVE ALPHA 1A/1D ADRENORECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY AND LOWER URINARY TRACT SYMPTOMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
| US-20040023938-A1 | Sulfonamide derivatives | TABUCHI TAKANORI (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6586617-B1 | Nontoxic microbiocides such as 4'-chloro-N-ethyl-2'-nitro-p-toluenesulfonanilide, for agricultural or horticultural, prepared by alkylation or nitration | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1174028-A1 | SULFONAMIDE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173015-A1 | Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | ADRA1D, ADRA1A, ADRB1 | CA2 2458/4885MMP2 3355/4885CA1 4138/4885 |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | CA2 2654/4885MMP2 4345/4885CA1 4378/4885 |
| US-20040023938-A1 | Sulfonamide derivatives | FPR1, MRM1, SULT1E1 | CA2 790/4885MMP2 3384/4885CA1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.